Solara Active Pharma Sciences Limited (NSE:SOLARAPP1)
India · Delayed Price · Currency is INR 449.85
+3.00 (0.67%)
At close: Aug 1, 2025, 3:30 PM IST
NSE:SOLARAPP1 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2018 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2018 - 2021 |
| 12,394 | 12,838 | 12,889 | 14,438 | 12,683 | 16,169 | Upgrade | |
Revenue Growth (YoY) | -4.67% | -0.40% | -10.73% | 13.84% | -21.56% | 22.33% | Upgrade |
Cost of Revenue | 5,713 | 6,264 | 8,629 | 8,389 | 7,079 | 7,705 | Upgrade |
Gross Profit | 6,681 | 6,574 | 4,261 | 6,049 | 5,605 | 8,464 | Upgrade |
Selling, General & Admin | 2,103 | 2,117 | 2,500 | 2,308 | 2,392 | 2,327 | Upgrade |
Other Operating Expenses | 2,364 | 2,394 | 2,703 | 2,353 | 2,349 | 2,205 | Upgrade |
Operating Expenses | 5,445 | 5,503 | 6,236 | 5,773 | 5,864 | 5,618 | Upgrade |
Operating Income | 1,236 | 1,070 | -1,975 | 275.9 | -259.9 | 2,846 | Upgrade |
Interest Expense | -1,078 | -1,148 | -1,001 | -868 | -724.2 | -803.4 | Upgrade |
Interest & Investment Income | - | - | 22.2 | 57.8 | 77.6 | 142.2 | Upgrade |
Currency Exchange Gain (Loss) | - | - | 6.7 | 2.7 | 24.2 | -16.9 | Upgrade |
Other Non Operating Income (Expenses) | 87.4 | 83.2 | -47.8 | -20.7 | -8.2 | -13.8 | Upgrade |
EBT Excluding Unusual Items | 245.2 | 5.4 | -2,995 | -552.3 | -890.5 | 2,154 | Upgrade |
Merger & Restructuring Charges | - | - | - | - | -34.9 | - | Upgrade |
Gain (Loss) on Sale of Assets | - | - | 3.6 | -4.5 | -7.7 | 20 | Upgrade |
Other Unusual Items | - | - | -1,897 | 100.2 | 17.5 | 38.2 | Upgrade |
Pretax Income | 245.2 | 5.4 | -4,884 | -448.2 | -911 | 2,215 | Upgrade |
Income Tax Expense | - | - | 785.4 | -225.7 | -328.1 | 1.5 | Upgrade |
Earnings From Continuing Operations | 245.2 | 5.4 | -5,670 | -222.5 | -582.9 | 2,214 | Upgrade |
Net Income to Company | 245.2 | 5.4 | -5,670 | -222.5 | -582.9 | 2,214 | Upgrade |
Minority Interest in Earnings | - | - | -4.3 | 0.7 | 1.4 | 0.5 | Upgrade |
Net Income | 245.2 | 5.4 | -5,674 | -221.8 | -581.5 | 2,214 | Upgrade |
Net Income to Common | 245.2 | 5.4 | -5,674 | -221.8 | -581.5 | 2,214 | Upgrade |
Net Income Growth | - | - | - | - | - | 93.18% | Upgrade |
Shares Outstanding (Basic) | 40 | 39 | 36 | 36 | 36 | 32 | Upgrade |
Shares Outstanding (Diluted) | 40 | 39 | 36 | 36 | 36 | 34 | Upgrade |
Shares Change (YoY) | 10.64% | 7.15% | - | 0.15% | 4.75% | 28.19% | Upgrade |
EPS (Basic) | 6.18 | 0.14 | -157.62 | -6.16 | -16.18 | 69.00 | Upgrade |
EPS (Diluted) | 6.18 | 0.14 | -157.62 | -6.16 | -16.18 | 64.53 | Upgrade |
EPS Growth | - | - | - | - | - | 50.70% | Upgrade |
Free Cash Flow | - | 1,729 | 678.1 | 449.4 | -4,507 | -190.2 | Upgrade |
Free Cash Flow Per Share | - | 44.82 | 18.84 | 12.48 | -125.38 | -5.54 | Upgrade |
Dividend Per Share | - | - | - | - | - | 7.000 | Upgrade |
Dividend Growth | - | - | - | - | - | 250.00% | Upgrade |
Gross Margin | 53.91% | 51.20% | 33.06% | 41.90% | 44.19% | 52.35% | Upgrade |
Operating Margin | 9.97% | 8.34% | -15.33% | 1.91% | -2.05% | 17.60% | Upgrade |
Profit Margin | 1.98% | 0.04% | -44.02% | -1.54% | -4.58% | 13.69% | Upgrade |
Free Cash Flow Margin | - | 13.47% | 5.26% | 3.11% | -35.53% | -1.18% | Upgrade |
EBITDA | 2,228 | 2,063 | -979.8 | 1,315 | 793.3 | 3,872 | Upgrade |
EBITDA Margin | 17.98% | 16.07% | -7.60% | 9.11% | 6.25% | 23.95% | Upgrade |
D&A For EBITDA | 991.73 | 992.5 | 995.6 | 1,039 | 1,053 | 1,026 | Upgrade |
EBIT | 1,236 | 1,070 | -1,975 | 275.9 | -259.9 | 2,846 | Upgrade |
EBIT Margin | 9.97% | 8.34% | -15.33% | 1.91% | -2.05% | 17.60% | Upgrade |
Effective Tax Rate | - | - | - | - | - | 0.07% | Upgrade |
Revenue as Reported | 12,482 | 12,921 | 12,943 | 14,664 | 12,884 | 16,457 | Upgrade |
Advertising Expenses | - | - | 33 | 8.6 | 3.8 | 3.1 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.